Loss widens sharply. Dianthus Therapeutics, Inc. (DNTH) reported a loss of $1.43 per share for Q4 2025, wider than the expected loss of $1.03 per share. The biotech posted a net loss of $64.4 million for the quarter. The wider-than-expected loss marks a significant deterioration from the prior quarter’s $0.97 per share loss and $0.81 per share loss reported in Q4 2024.
Revenue collapses year-over-year. The company generated just $280,000 in revenue for the quarter, down 78.9% from $1.3 million in the year-ago period. Sequentially, revenue declined from Q3 2025’s $396,000. The minimal revenue base reflects the company’s early-stage development profile, with the business still heavily dependent on research milestones rather than commercial product sales. Despite the operational losses, shares surged 21.5% on volume of 4.6 million shares, suggesting investors are focused on pipeline developments rather than near-term profitability.
What to Watch: Q1 2026 estimates call for a loss of $0.91 per share on revenue of $470,000 — track the upcoming earnings call for updates on clinical trial timelines and cash runway, which will determine whether the biotech can reach key development milestones without additional dilutive financing.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
Source link
#Dianthus #Therapeutics #DNTH #Earnings #Results
